Search company, investor...


Founded Year



Series C | Alive

Total Raised


Last Raised

$4.62M | 8 yrs ago

About Protagen

Protagen uses its proprietary SeroTag biomarker platform to identify disease specific autoantibodies and is on target to become the leading provider of autoimmune diagnostic products, specifically targeting diseases with an unmet need for effective diagnostics. With pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen works to develop its own diagnostic pipeline and partners with other organizations to develop and implement new companion diagnostic tools for better personalized treatment strategies.

Headquarters Location

Otto-Hahn-Str. 15

Dortmund, D-44227,


+49 231 9742 6300

Missing: Protagen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Protagen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Protagen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Protagen is included in 2 Expert Collections, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

2,530 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Protagen Patents

Protagen has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Arthritis
  • Inflammations
patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Rheumatology, Autoantibodies, Immunology, Immune system


Application Date


Grant Date



Related Topics

Autoimmune diseases, Rheumatology, Autoantibodies, Immunology, Immune system



Latest Protagen News

Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene

May 17, 2022

Heilbronn & Heidelberg, Germany and Boston, USA – January 12, 2022: Following the announced merger in July 2021, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH today announced their unified operations and re-brand as ProtaGene, a world-leading CRO partner for the biopharmaceutical and cell & gene therapy industries. The three legacy companies’ combined strength and experience provides the most advanced, integrated, and complete protein and gene analytic service offering for biological therapeutics and cell & gene therapy platforms, all the way from discovery to commercialization. Protagen Protein Services, a leading global analytic CRO and expert in protein science, and BioAnalytix, a U.S.-based advanced analytics and data analysis firm, combined in April 2019. GeneWerk, with unique capabilities in vector safety, integration site analysis, and bioinformatics, merged into the group in 2021, creating ProtaGene, a portfolio company of Ampersand Capital Partners. Martin Blüggel, CEO of ProtaGene and the founder of Protagen Protein Services, said: “We are very excited to launch ProtaGene. The track record and reputation of the three legacy entities are individually impressive, and their combination into a single, globally integrated business delivers significant compounded value for our sponsors. Our new scale and breadth of expertise will benefit the impressive list of innovative products we support, both in development and on the market, and ultimately deliver for patients worldwide. We are passionate in our vision to establish ProtaGene as the world’s leading CRO partner in biologics and cell & gene therapy markets.” Kirtland Poss, CEO-US of ProtaGene and the founder of BioAnalytix, added, “Our collective expertise and unwavering delivery in both protein and gene analytics are well established. By combining our capabilities, platforms and knowledge, we can now provide our U.S.-based biopharmaceutical and gene therapy customers advanced access to the broadest analytical offering from discovery to market, from a single vendor relationship.” Annette Deichmann, Senior Vice President of Cell & Gene Therapy at ProtaGene and the co-founder of GeneWerk, said: “We are delighted to embark on this journey, where we will continue to employ our unique expertise and method innovation in cell & gene therapy. Our unique experience in gene analytics – especially integration site analysis, vector purity, vector copy numbers, and bioinformatics analysis for preclinical development and clinical trials – will support many innovators in taking breakthrough therapies to the clinic.” ProtaGene also launched a new corporate website at . About ProtaGene ProtaGene is a world leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From discovery to product commercialization, ProtaGene provides the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics and cell & gene therapy platforms. A unique combination of protein- and gene-based analytical platforms make ProtaGene the leading analytic service provider in biologics and cell & gene therapy development. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide. Additional information is available at . About Ampersand Capital Partners Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at . Media Agency Contact:

Protagen Frequently Asked Questions (FAQ)

  • When was Protagen founded?

    Protagen was founded in 1997.

  • Where is Protagen's headquarters?

    Protagen's headquarters is located at Otto-Hahn-Str. 15, Dortmund.

  • What is Protagen's latest funding round?

    Protagen's latest funding round is Series C.

  • How much did Protagen raise?

    Protagen raised a total of $22.62M.

  • Who are the investors of Protagen?

    Investors of Protagen include MIG Verwaltungs, NRW.Bank, QIAGEN, S-Venture Capital Dortmund and KfW.

  • Who are Protagen's competitors?

    Competitors of Protagen include Five Prime Therapeutics, Blue Sky BioServices, Proteostasis Therapeutics, Protein Solutions, Pronota and 9 more.

Compare Protagen to Competitors

ProFoldin Protein Folding Services

ProFoldin Protein Folding Services is committed to providing professional services and research tools to academic institutes, biotech and pharmaceutical industries in the area of protein sciences. One of the company's focus area is to help the company's customers to make active proteins from inactive ones, a process called protein folding. ProFoldin aims to provide protein folding columns and reagents and performs customer protein folding services.

Pronota Logo

Pronota has developed and implemented an integrated protein biomarker pipeline applying protein chemistry techniques, advanced separation sciences and high-end mass spectrometry. The two components, MASStermind for low abundance protein biomarker discovery and MASSterclass for antibody free, multiplex protein assay development aimto provide a solution for the discovery and verification of high value biomarkers for drug and diagnostic development.


Proteomics is widely viewed as the cornerstone of future success in drug discovery and clinical diagnostics, but the complexity of protein molecules and their interactions requires new tools to find and understand biomarkers and protein functions. A critical step in the research process is to properly prepare the molecular sample before analysis can begin. Proteopure, Inc.'s technology is the foundation of a simple laboratory "kit" that fills unmet research needs.nProteopure developed and is now marketing sample protein preparation kits. In addition, Proteopure markets complementary products where there is overlapping customer synergy. These other products include a kit for membrane sample preparation, a kit for measuring protein concentration, fluorescent nanoclusters and beads for labeling proteins, and fluorescent tagged genes for measuring protein expression and location.


BioSilta, founded in 2007 in Oulu, Finland, utilizes its unique, proprietary EnBase technology platform to develop innovative, reagent-based EnPresso growth systems. When compared to conventional growth media, these growth systems significantly increase the yield of high quality biomolecules from microbial cultures.

LifeSensors Logo

LifeSensors is a biotechnology company located 35 miles west of Philadelphia, Pennsylvania, USA. Founded in 1996, LifeSensors has developed a number of protein expression technologies that enable efficient translation of the genome into proteome.LifeSensors is well-known for its innovations in an important family of proteins consisting of ubiquitin and ubiquitin-like proteins (UBL) such as SUMO (Small Ubiquitin-like MOdifier).LifeSensors has been granted several patents to cover the use of SUMO and other UBLs as gene fusion tags to improve the expression and purification of recombinant proteins. Additional patent applications are in various stages of review. Currently, LifeSensors is expanding its protein production capabilities and is developing protein micro array for drug discovery and diagnostics.


PrimeraDx, formerly Primera Biosystems, is developing a platform and companion assays for quantitative multiplex molecular diagnostics that aims to enable improved patient management and reduced overall healthcare costs in the areas of infectious disease and oncology. Primera's assays and instrument systems are based on the company's STAR "Scalable Target Analysis Routine" technology, which aims to enable simultaneous quantitative measurement of up to 60 genes in a single assay by real-time PCR with appropriate sensitivity, accuracy and specificity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.